Doxorubicin and PD-L1 siRNA co-delivery with stem cell membrane-coated polydopamine nanoparticles for the targeted chemoimmunotherapy of PCa bone metastases

Citations Over TimeTop 10% of 2021 papers

Abstract

Programmed cell death ligand 1 (PD-L1) blockade has achieved great success in cancer immunotherapy. PD-L1 siRNA can restore the immune anti-tumor activity of T cells by downregulating the level of PD-L1 on tumor cells, but the efficiency of PD-1/PD-L1 monotherapy is relatively low. Doxorubicin (DOX) can induce tumor cell apoptosis, and then increase the release of tumor antigen. But the expression of PD-L1 in tumor tissues treated with DOX will be enhanced adaptively. Therefore, DOX combination with PD-L1 siRNA can produce a good synergistic anti-tumor effect. In this study, stem cell membrane (SCM) camouflaged polydopamine nanoparticles carrying DOX and PD-L1 siRNA (PDA-DOX/siPD-L1@SCM) were constructed for targeting prostate cancer (PCa) bone metastases. PDA-DOX/siPD-L1@SCM NPs could effectively enhance blood retention and improve accumulation at tumor sites. In vitro and in vivo studies demonstrated that PDA-DOX/siPD-L1@SCM NPs showed excellent performance in synergistic chemoimmunotherapy for PCa bone metastases. Hence, this study provided an effective strategy for developing biomimetic multifunctional nanoparticles for PCa bone metastasis treatment.

Related Papers

• → Is There a Role for Chemotherapy in the Era of Targeted Therapies?(2020)6 cited
• Regional chemoimmunotherapy for nonresectable metastatic liver disease of colorectal origin. A prospective randomized study.(2001)
• Chemoimmunotherapy with Krestin in acute leukemia.(1981)
• → Results of a Nonrandomized Trial in Malignant Melanoma Patients (Clark’s Stages III–V) Treated by Post-Surgical Chemoimmunotherapy(1979)8 cited
• → [Application of Neoadjuvant Chemoimmunotherapy in Resectable NSCLC].(2023)1 cited